Longboard pharmaceuticals' presence at american epilepsy society (aes) annual meeting reinforces ongoing commitment to the rare epilepsy community

La jolla, calif.--( business wire )--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for lp352, a novel, highly selective investigational treatment in development for seizures associated with a range of developmental and epileptic encephalopathies (dees), in two poster sessions at the 2022 aes annual meeting. longboard will also host a scientific exhibit with members of its leadership team to highlight details of the ongoing pacific study, and to discuss lp352 as a potential best-in-class therapy for people living with rare seizure disorders.
LBPH Ratings Summary
LBPH Quant Ranking